Cancer Genetics (CGIX) Lifted to “Buy” at ValuEngine

Cancer Genetics (NASDAQ:CGIX) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, February 4th.

Separately, Maxim Group restated a “hold” rating on shares of Cancer Genetics in a research report on Tuesday, November 20th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $4.50.

Shares of Cancer Genetics stock traded down $0.01 on Monday, reaching $0.26. The company’s stock had a trading volume of 716,257 shares, compared to its average volume of 2,745,635. The stock has a market capitalization of $6.93 million, a PE ratio of -0.33 and a beta of 1.18. Cancer Genetics has a 52-week low of $0.20 and a 52-week high of $2.20. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.46 and a quick ratio of 0.46.

In related news, CEO John A. Roberts acquired 185,436 shares of the stock in a transaction on Thursday, January 31st. The shares were bought at an average price of $0.23 per share, with a total value of $42,650.28. Following the completion of the purchase, the chief executive officer now owns 297,636 shares of the company’s stock, valued at approximately $68,456.28. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Pappajohn acquired 1,000,000 shares of the stock in a transaction on Monday, January 14th. The shares were bought at an average cost of $0.23 per share, for a total transaction of $230,000.00. Following the purchase, the director now directly owns 3,781,204 shares of the company’s stock, valued at approximately $869,676.92. The disclosure for this purchase can be found here. Insiders have purchased 2,435,436 shares of company stock valued at $560,150 over the last quarter. 21.30% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CGIX. Geode Capital Management LLC lifted its stake in shares of Cancer Genetics by 106.6% in the 4th quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 114,448 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Cancer Genetics by 22.0% in the 2nd quarter. Renaissance Technologies LLC now owns 587,300 shares of the medical research company’s stock valued at $523,000 after purchasing an additional 105,900 shares during the last quarter. Vanguard Group Inc lifted its stake in shares of Cancer Genetics by 119.8% in the 3rd quarter. Vanguard Group Inc now owns 532,426 shares of the medical research company’s stock valued at $554,000 after purchasing an additional 290,146 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Cancer Genetics by 119.8% in the 3rd quarter. Vanguard Group Inc. now owns 532,426 shares of the medical research company’s stock valued at $554,000 after purchasing an additional 290,146 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its stake in shares of Cancer Genetics by 28.1% in the 3rd quarter. Perkins Capital Management Inc. now owns 1,287,250 shares of the medical research company’s stock valued at $1,339,000 after purchasing an additional 282,700 shares during the last quarter. 11.46% of the stock is currently owned by institutional investors.

Cancer Genetics Company Profile

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Featured Article: How to Invest in the Dividend Aristocrat Index

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.